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High frequency of CHD7 mutations 
in congenital hypogonadotropic 
hypogonadism
Catarina Inês Gonçalves1, Filipa Marina patriarca1, José Maria Aragüés2, Davide Carvalho3, 
Fernando Fonseca4, Sofia Martins5, olinda Marques6, Bernardo Dias pereira7, José Martinez-
de-oliveira1 & Manuel Carlos Lemos  1
Congenital hypogonadotropic hypogonadism (CHH) is characterized by lack of normal pubertal 
development due to deficient gonadotropin-releasing hormone (GnRH) secretion or action, and is 
caused by genetic defects in several genes. Mutations in the CHD7 gene cause CHARGe syndrome 
(Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and development, 
Genital hypoplasia and ear abnormalities), but have also been found in patients with isolated CHH. 
the aim of this study was to identify CHD7 mutations in patients with CHH. Fifty portuguese patients 
with CHH were screened for mutations in the CHD7 gene by DNA sequencing. Eight (16%) patients had 
CHD7 rare sequence variants that consisted of six missense (p.Gly388Glu, p.His903Pro, p.Thr1082Ile, 
p.Val1452Leu, p.Asp1854Gly, and p.Arg2065His) and two synonymous (p.Ser559Ser, and p.Ala2785Ala) 
mutations. Five of these mutations have never been reported before. three CHD7 mutations occurred 
in patients that had mutations in additional CHH-genes. this study uncovered novel genetic variants 
that expand the known spectrum of mutations associated with CHH. the frequency of CHD7 mutations 
in this cohort was higher than that of other major CHH-genes and confirms the importance of including 
CHD7 in the genetic testing of CHH, even in the absence of additional CHARGe features.
Congenital hypogonadotropic hypogonadism (CHH) is characterized by partial or complete lack of pubertal 
development, secondary to deficient gonadotropin-releasing hormone (GnRH) induced gonadotropin secretion1. 
The diagnosis is based on the existence of low levels of sex hormones associated with low or inappropriately 
normal levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). CHH may occur associated 
with anosmia, a condition referred to as Kallmann syndrome (KS), or may occur without associated olfactory 
abnormalities, referred to as normosmic CHH (nCHH)1.
Monogenic or oligogenic defects are found in about 50% of patients with CHH, in genes that regulate 
the embryonic development or migration of GnRH neurons, or the synthesis, secretion or action of GnRH2. 
Mutations in the ANOS1 (KAL1) (MIM 300836), FGFR1 (KAL2) (MIM 136350) and GNRHR (MIM 138850) 
genes have been the most frequently reported, but there are now over 30 genes that have been associated with 
CHH. However, most of these genes are rarely involved in CHH and even the most commonly implicated genes 
usually account for less than 10% of cases2.
CHARGE syndrome is a rare disorder characterized by a variable combination of congenital anomalies that 
include Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and development, 
Genital hypoplasia and Ear abnormalities3. Heterozygous loss-of-function mutations in the chromodomain 
helicase DNA-binding protein 7 (CHD7) gene (MIM 608892) are the major cause of CHARGE syndrome4. 
Hypogonadotropic hypogonadism and olfactory defects, which are the hallmarks of KS, are commonly observed 
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in CHARGE syndrome5 and CHD7 mutations have been identified in patients with isolated CHH (i.e. without 
additional CHARGE features)6–11.
The aim of this study was to determine the frequency of CHD7 mutations in a cohort of patients with isolated CHH.
Material and Methods
subjects. The study comprised 50 unrelated Portuguese patients with CHH (42 men and 8 women, mean 
age at diagnosis 21.4 years, range 14–45 years), 22 with KS and 28 with nCHH, recruited by Portuguese clinical 
endocrine centers. Inclusion criteria were patients with low or inappropriately normal serum FSH, LH and sex 
steroid levels, failure to enter spontaneous puberty by the age of 18 years or with medically induced puberty below 
this age, and absence of other pituitary hormone deficiencies. Olfactory function was assessed either by olfaction 
testing or self-reported by the patients, depending on the clinical center. None of the patients had diagnostic 
criteria for CHARGE syndrome12. In mutation-positive patients, additional family members were studied, when 
available. The control population consisted of >200 Portuguese unrelated healthy volunteers who were recruited 
among blood donors. The study was approved by the local research ethics committee (Faculty of Health Sciences, 
University of Beira Interior, Ref: CE-FCS-2012-012). Written informed consent was obtained from all subjects 
and all methods were performed in accordance with the relevant guidelines and regulations.
Genetic studies. Genomic deoxyribonucleic acid (DNA) was extracted from peripheral blood leucocytes 
using previously described methods13. Patients had already been screened for mutations in the ANOS1, FGFR1 
and GNRHR genes, resulting in the discovery of three mutations in ANOS114, six mutations in FGFR115 and six 
mutations in GNRHR16. All 50 patients were subsequently screened for mutations in the CHD7 gene by poly-
merase chain reaction (PCR) amplification of the coding exons and exon-intron boundaries, and bi-directional 
sequencing using CEQ DTCS sequencing kit (Beckman Coulter, Fullerton, CA, USA) and an automated capillary 
DNA sequencer (GenomeLab TM GeXP, Genetic Analysis System, Beckman Coulter). Primer sequences for 
CHD7 were previously described by Song et al.17, except for the primer sequence of exons 2.4 and 3, which were 
designed using Primer 3 Plus18. Genomic sequence variants identified in patients were searched in the Exome 
Aggregation Consortium (ExAC) population variant database19, to assess their frequency in the general popu-
lation. Variants found to be absent in the ExAC database or with frequencies <0.1% were further screened in a 
panel of at least 200 healthy Portuguese volunteers (400 alleles), using allele-specific PCR or sequence-specific 
restriction enzymes, to exclude the possibility that they represented common polymorphisms in the Portuguese 
population. Variants were considered to be pathogenic when they were simultaneously found to have an ExAC 
population frequency <0.1%, to be absent in the Portuguese control population, and to have a deleterious effect 
predicted by at least one of four bioinformatic programs (SIFT20, PolyPhen-221, Mutation Taster22 or Human 
Splicing Finder23). Sequence variant nomenclature followed standard guidelines24 and was based on the cDNA 
reference sequence for the CHD7 gene (GenBank accession NM_017780.3). Patients with pathogenic variants in 
CHD7 were further screened for mutations in additional genes related to the hypothalamic–pituitary–gonadal 
axis (PROKR2, PROK2, FGF8, GNRH1, KISS1R, TAC3 and TACR3), to identify possible cases of oligogenicity 
(primer sequences and PCR conditions are available upon request).
Results
Sequence analysis of the entire coding region and exon–intron boundaries of CHD7 revealed 13 heterozygous 
variants that had frequencies <0.1% in the ExAC population database. Five of these variants were detected in 
normal Portuguese controls (p.Thr689Thr, 2 of 408 alleles; p.Lys729Glu, 1 of 436 alleles; c.2613 + 4 C > T, 1 of 454 
alleles; p.Gly1479Gly, 1 of 398 alleles; p.Pro2072Pro, 1 of 450 alleles) and were excluded from further analysis. 
The remaining eight variants were found to be absent in the Portuguese control population and were predicted 
to cause changes in protein function, by at least one bioinformatic prediction program (Table 1). Thus, 16% (8 
out of 50) of patients with CHH were considered to have pathogenic variants in CHD7. Mutations occurred in 
both KS (4/22, 18%) and nCHH (4/28, 14%). Mutations consisted of six missense (c.1163 G > A, p.Gly388Glu; 
CHD7 variant
Population allele frequency 
(ExAC/Portuguese)(a)
Computational programs that 
support a pathogenic effect(b) Additional genetic variants
Missense
c.1163 G > A; p.Gly388Glu 0.0008%/0% SIFT, PP2, MT
c.2708 A > C; p.His903Pro 0%/0% SIFT, PP2, MT
c.3245 C > T; p.Thr1082Ile 0%/0% SIFT, PP2, MT FGFR1 c.12 G > T and PROKR2 c.802 C > T(c)
c.4354 G > T; p.Val1452Leu 0%/0% MT
c.5561 A > G; p.Asp1854Gly 0%/0% SIFT, PP2, MT FGFR1 c.177 C > T
c.6194 G > A; p.Arg2065His 0%/0% SIFT, PP2, MT
Synonymous
c.1677G > A; p.Ser559Ser 0.0036%/0% MT, HSF
c.8355 C > T; p.Ala2785Ala 0.0074%/0% MT, HSF FGFR1 c.600 C > T and PROKR2 c.528 G > C
Table 1. Rare sequence variants predicted to be pathogenic by at least one computational program. (a)ExAC 
Exome Aggregation Consortium frequency/Portuguese control population. (b)SIFT, Sorting Tolerant From 
Intolerant; PP2, PolyPhen-2; MT, Mutation Taster; HSF, Human Splicing Finder. (c)Patient previously reported 
by Gonçalves et al.15.
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c.2708 A > C, p.His903Pro; c.3245 C > T, p.Thr1082Ile; c.4354 G > T, p.Val1452Leu; c.5561 A > G, p.Asp1854Gly; 
c.6194 G > A, p.Arg2065His) and two synonymous (c.1677G > A, p.Ser559Ser; c.8355 C > T, p.Ala2785Ala) 
variants (Fig. 1). Conservation analysis revealed that, with the exception of p.Gly388Glu, all missense variants 
occurred at amino acids that were highly conserved across species (Supplemental Table 1).
Figure 1. CHD7 mutations identified in patients with CHH. Arrows represent index cases, filled symbols 
represent affected individuals, open symbols represent unaffected individuals, squares denote men, circles denote 
women, oblique lines through symbols represent deceased individuals. Filled squares within squares represent 
individuals reported to have heart defects associated with polydactyly. Patients from families 3, 5 and 8 had 
mutations in additional genes, thus representing cases of oligogenicity. Genotypes for additional family members, 
when available, are presented beside each individual (+, wild-type allele; −, mutated allele; n/a, not available for 
genetic studies). The position of each heterozygous mutation on the DNA sequence is indicated by an asterisk.
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The p.Ser559Ser, p.Arg2065His and p.Ala2785Ala variants, have been previously identified in patients with 
CHARGE syndrome25. The remaining five variants have not yet been reported in patients with either CHH or 
CHARGE syndrome.
In six of the eight families, it was possible to determine the parental origin of the CHD7 mutation and in all 
six cases the mutation was transmitted by a parent who did not have CHARGE symptoms or a history of delayed 
puberty (Fig. 1). In three of these cases, patients presented mutations in additional CHH genes, namely one 
digenic mutation (CHD7/FGFR1) and two trigenic mutations (CHD7/FGFR1/PROKR2), thus representing cases 
of oligogenic inheritance (Fig. 1).
All CHD7 variants were submitted to the CHD7 mutation database at www.chd7.org.
The clinical characteristics of patients with identified CHD7 pathogenic variants are summarized in Table 2.
Discussion
The overall prevalence of CHD7 mutations in this cohort of Portuguese patients with CHH was 16% (8 out of 
50), with a similar distribution between the KS and nCHH forms. This is a high prevalence when compared to 
the contribution of other genes that have been historically considered as priorities in the genetic study of CHH, 
namely the ANOS1 (KAL1), FGFR1, and GNRHR genes26. Indeed, previous studies in the Portuguese population 
have shown that the ANOS1 (KAL1), FGFR1, and GNRHR genes are mutated in only 7.1%, 12.0%, and 12.5% of 
cases, respectively14–16. Studies in other populations have also shown an important contribution of CHD7 muta-
tions in the aetiology of CHH, with frequencies ranging from 5.2% to 19.0%, of cases6–11. Thus, the CHD7 gene is 
becoming increasingly recognised as one of the most commonly mutated genes in CHH.
Although CHD7 mutations can cause both CHARGE syndrome and isolated CHH, it is likely that this variable 
phenotypic expression is related to the severity of the CHD7 mutations, as mutations in CHARGE syndrome are 
typically highly deleterious protein-truncating mutations, whereas CHD7 mutations in isolated CHH are typi-
cally missense8. Accordingly, in our CHH patients, all identified CHD7 mutations were either missense (n = 6) 
or synonymous (n = 2).
The eight CHD7 mutations identified in this study were found to be absent or very rare (<0.1%) in the 
ExAC population database19, absent in Portuguese controls, and predicted to be damaging by structure- and 




(yrs) Clinical presentation Olfaction Associated features
Basal hormone levels 
(laboratory normal 








FSH 0.29 mIU/mL 
(1.1–13.6); LH < 0.07 
mIU/mL (1.1–8.8); total T 
0.34 ng/mL (2.8–11.1)
Pituitary hypoplasia CHD7 c.1163 G > A, p.(Gly388Glu)
2 M 14 Micropenis and delayed puberty Normal — n/a Normal
CHD7 c.2708 A > C, 
p.(His903Pro)
3 M 19 Arrested puberty Normal
Osteoporosis and osteopenia 
(lumbar spine Z-score −2.6; 
femoral neck Z-score −2.1).
FSH 2.6 mIU/mL (1.0–
12.0); LH 2.0 mIU/mL 
(1.0–7.0); total T 0.32 ng/
mL (2.60–10.00)
Normal
CHD7 c.3245 C > T, 
p.(Thr1082Ile) and FGFR1 
c.12 G > T, p.(Trp4Cys) 
and PROKR2 c.802 C > T, 
p.(Arg268Cys)
4 M 21 Delayed puberty Anosmia
Reversal of hypogonadism 
after testosterone replacement 
therapy (age 33 yrs).
FSH 1.7 mIU/mL 
(1.5–12.0); LH 0.9 mIU/
mL (1.0–8.5); total T 
0.7 ng/mL (2.6–16.0)





Anosmia Mild hearing deficit.
FSH < 0.3 mIU/mL 
(1.4–10.0); LH < 0.07 
mIU/mL (1.5–9.3); total 
T < 0.2 ng/mL (2.4–8.3)
Normal
CHD7 c.5561 A > G, 
p.(Asp1854Gly) and FGFR1 
c.177 C > T, p.(Asp59Asp)
6 M 16 Cryptorchidism and delayed puberty Anosmia
Recurrent pyelonephritis. 
Renal transplant due to 
chronic renal failure (age 
43 yrs).
FSH 3.4 mIU/mL 
(5.0–25.0); LH 1.9 mIU/
mL (5.0–30.0); total T 
0.87 ng/mL (2.50–7.50)
Normal CHD7 c.6194 G > A, p.(Arg2065His)
7 M 15 Micropenis and delayed puberty Normal
Psicomotor developmental 
delay. Strabismus. Surgery 
for deviated nasal septum 
and hypertrophy. Reversal 
of hypogonadism after 
testosterone replacement 
therapy (age 18 yrs).
FSH 0.71 mIU/mL 
(0.8–8.2); LH < 0.07 mIU/
mL (0.7–7.2); total T 
0.22 ng/mL (2.20–8.00)
Normal CHD7 c.1677G > A, p.(Ser559Ser)
8 M 17 Delayed puberty Normal —
FSH 0.3 mIU/mL (0.8–
8.2); LH < 0.1 mIU/mL 
(0.7–7.2); total T 0.05 ng/
mL (2.20–8.00)
Pituitary hypoplasia
CHD7 c.8355 C > T, 
p.(Ala2785Ala) and FGFR1 
c.600 C > T, p.(Asp200Asp) 
and PROKR2 c.528 G > C, 
p.(Leu176Phe)
Table 2. Clinical characteristics of patients with CHD7 rare sequence variants. M, male; yrs, years; FSH, 
follicle stimulating hormone; LH, luteinizing hormone; T, testosterone; MRI, magnetic resonance imaging; 
CT, computerized tomography; n/a, not available. Hormone levels are only presented for gonadotrophins and 
testosterone, all other pituitary hormone measurements were normal.
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have already been reported in patients with CHARGE syndrome25, and the remaining five missense mutations 
have not yet been reported in patients with either CHH or CHARGE syndrome. The missense mutations occurred 
at highly conserved amino acids. Furthermore, the p.His903Pro, p.Thr1082Ile and p.Val1452Leu mutations are 
located in chromodomain 2, the SNF2 domain and the helicase domain, respectively, which play important roles 
in the chromatin remodelling activity of the CHD7 protein6. The remaining missense mutations occurred outside 
these catalytic domains but were also predicted to affect protein function. The mechanisms by which the synony-
mous mutations exert their effect were not possible to determine. However, synonymous mutations - sometimes 
called ‘silent’ mutations - are widely acknowledged to be able to cause changes in protein expression, conforma-
tion and function, and have been implicated in several diseases27. It should be noted however that according to 
more stringent classification criteria recommended by the American College of Medical Genetics and Genomics 
(ACMG)28, only the p.Thr1082Ile variant is considered “likely pathogenic” and the remaining are considered 
“variants of uncertain significance”.
Three patients with CHD7 mutations presented additional defects in known CHH-genes. Thus, these repre-
sent cases of oligogenic inheritance, which is a frequent genetic finding in CHH29. Oligogenicity might explain 
some cases of incomplete penetrance, where carriers of a CHD7 mutation only express CHH in the presence of 
other mutated genes.
Our patients with CHD7 mutations did not undergo detailed radiological investigations to detect hypoplasia/
agenesis of semicircular canals or of olfactory bulbs and tracts, which are currently major criteria for CHARGE 
syndrome30,31. Thus, we cannot exclude that patients have light forms of CHARGE syndrome. Other studies have 
shown that a subset of patients with apparently isolated CHH, in whom a CHD7 defect was demonstrated, were 
subsequently found to exhibit multiple CHARGE features and reclassified as having CHARGE syndrome32–34. 
Interestingly, three of our patients with CHD7 mutations had minor CHARGE features30,31, namely hearing defi-
cit, renal anomalies and intellectual disability, respectively, but insufficient for a clinical diagnosis of CHARGE 
syndrome. It remains to be determined if these were coincidental findings or the result of the CHD7 mutations.
Our results should be viewed with caution as in vitro and in vivo functional tests are not readily available for 
CHD735, and therefore it was not possible to confirm the damaging effect of the observed CHD7 variants. In 
addition, a limited number of CHH-genes was analysed by Sanger sequencing and it remains to be determined if 
a more comprehensive genetic analysis (e.g. through whole exome sequencing) would uncover additional cases of 
oligogenicity and explain the incomplete penetrance observed in some families. Finally, CHH is clinically hetero-
geneous and sometimes overlaps with constitutional delay of growth and puberty (CDGP)36. Our study included 
patients with a wide range of ages and we cannot exclude the possibility that some of the younger patients, who 
underwent medically induced puberty, may represent cases of CDGP or mild forms of CHH that would have 
eventually developed spontaneous late puberty. Therefore, our results may not be directly comparable with those 
of other studies that used different inclusion criteria.
In conclusion, our study identified a high frequency of CHD7 mutations in patients with CHH and uncovered 
novel genetic variants that expand the known spectrum of mutations associated with CHH.
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